Treats major depressive disorder (MDD). ANDA 214609, held by Somerset Therapeutics. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 214609 (Venlafaxine Hydrochloride), held by Somerset Therapeutics, was first approved by FDA on Jun 30, 2021, with 1 approved supplement and 0 published complete response letters.
Venlafaxine extended-release tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 30, 2021 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 150MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 225MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Apr 9, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 30, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters